A Straightforward Answer to a Complicated Question
Psychedelic therapy — sometimes called psychedelic-assisted therapy — is the supervised use of psychedelic substances as part of a structured therapeutic process. The key word in that definition is "structured." It's not recreational drug use with a therapeutic label. It's not taking mushrooms at a music festival and calling it healing. And it's not a magic pill that fixes everything in one dose.
What it actually involves is a substance (most commonly psilocybin, ketamine, or historically MDMA) administered in a controlled setting, with trained professionals present, preceded by psychological preparation and followed by integration work designed to help make sense of and apply whatever surfaces during the experience.
That structure — preparation, substance-assisted session, integration — is what separates psychedelic therapy from psychedelic use more broadly, and it's what the clinical research showing promising results has actually studied. The substance is one component. The therapeutic framework around it is what makes it therapy.
How It Works — The Basic Model
Regardless of which substance is used, psychedelic therapy generally follows the same three-phase structure. Understanding this structure is more important than understanding any individual substance, because it's the framework that produces the outcomes the research has documented.
Phase 1 — Preparation. Before any substance is administered, you go through one or more sessions with a therapist or facilitator. These sessions cover your mental health history, current medications, what you're hoping to address, and what to expect during the experience. Preparation also involves practical elements: dietary guidelines, logistical planning, and establishing trust with the person who will be guiding your session.
This phase isn't optional or decorative. It directly affects the quality and safety of what follows. People who skip or rush preparation consistently report less meaningful outcomes and more difficult experiences.
Phase 2 — The Substance-Assisted Session. This is the part most people picture when they think of psychedelic therapy. You take the substance in a controlled environment — a licensed center, a clinical trial site, or a medical office depending on the substance — with a trained professional present throughout.
Sessions typically last several hours (the exact duration depends on the substance). During this time, you're in an altered state of consciousness that may involve vivid internal experiences, emotional intensity, shifts in perspective, and sometimes difficult material surfacing. The facilitator or therapist is there to ensure safety, provide support during difficult moments, and hold the space for whatever emerges.
Phase 3 — Integration. After the session, you work with a therapist or facilitator to process what surfaced and translate insights into actual changes in your life. This might involve several sessions over weeks or months. Integration is where the therapeutic value is either realized or lost — the substance creates an opening, but integration is what you do with it.
Most people who report lasting benefit from psychedelic therapy point to the integration phase as where the real work happened, not the session itself.
The Main Substances Used
Several substances fall under the umbrella of psychedelic therapy, each with different legal status, research profiles, and practical availability.
Psilocybin is the active compound in certain species of mushrooms, sometimes called "magic mushrooms." It's currently the most actively researched psychedelic for therapeutic purposes, with clinical trials at institutions like Johns Hopkins, Imperial College London, and NYU showing significant promise for treatment-resistant depression, end-of-life anxiety, and other conditions.
In the US, psilocybin is available through state-regulated programs in Oregon and Colorado, where licensed service centers offer supervised sessions to adults 21 and older without requiring a medical diagnosis. New Mexico's medical psilocybin program is expected to launch by the end of 2026. Psilocybin remains a Schedule I controlled substance under federal law everywhere else.
Ketamine is an FDA-approved anesthetic that's been used medically for decades. It's currently the only psychedelic-adjacent substance legal for therapeutic use in all 50 US states when administered by a licensed medical provider. Ketamine is used off-label for treatment-resistant depression, anxiety, PTSD, and chronic pain, typically administered as IV infusion, intramuscular injection, or sublingual lozenges in clinical settings.
A related compound, esketamine (brand name Spravato), received FDA approval as a nasal spray specifically for treatment-resistant depression in 2019, and as a monotherapy in January 2025. Unlike off-label ketamine, Spravato may be partially covered by insurance for qualifying patients.
MDMA (commonly known as ecstasy) was being studied primarily for PTSD treatment, with MAPS (Multidisciplinary Association for Psychedelic Studies) conducting major clinical trials. However, in August 2024, the FDA declined to approve MDMA-assisted therapy, citing concerns about trial design, blinding, and safety data. Additional trials are underway, with resubmission not expected before 2027. MDMA-assisted therapy is not currently available outside of active clinical trials in the US.
Other substances occasionally discussed in the context of psychedelic therapy include LSD (lysergic acid diethylamide), ayahuasca, ibogaine, and 5-MeO-DMT. Each has different research profiles, legal status, and availability. Most are not available through any legal pathway in the US, with the exception of specific religious exemptions for ayahuasca and some substances available through international retreat centers.
What the Research Actually Shows
The evidence base for psychedelic therapy has grown substantially over the past decade, but it's important to be specific about what the research has and hasn't demonstrated.
Strongest evidence — Psilocybin for depression. Multiple randomized controlled trials have shown significant antidepressant effects from psilocybin-assisted therapy, particularly in treatment-resistant depression. A 2022 multi-site trial published in the New England Journal of Medicine with 233 participants showed dose-dependent improvement. Follow-up studies from Johns Hopkins showed sustained benefit at 12 months from just two sessions. Effect sizes have been notably larger than those typically seen with conventional antidepressants.
Strong evidence — Psilocybin for end-of-life anxiety. Studies from Johns Hopkins and NYU showed that approximately 80 percent of cancer patients with life-threatening diagnoses showed sustained decreases in depression and anxiety at six-month follow-up from a single psilocybin session. Long-term follow-up found benefits persisting years later.
Moderate evidence — Ketamine for depression. Ketamine has the longest clinical track record of any psychedelic-adjacent substance for mental health. Its rapid-onset antidepressant effects are well-documented, though the effects of individual sessions tend to be shorter-lived than psilocybin's, typically requiring ongoing treatment series.
Developing evidence — Psilocybin for PTSD, addiction, and other conditions. Clinical trials are underway or in early stages for psilocybin-assisted therapy for PTSD, alcohol use disorder, tobacco addiction, OCD, and other conditions. Early results are promising but not yet at the level of evidence established for depression.
Setback — MDMA for PTSD. Despite initially promising phase 2 results, the FDA's August 2024 rejection of MDMA-assisted therapy highlighted that the path from research promise to approved treatment is neither guaranteed nor smooth. The field is working to address the methodological concerns the FDA raised, but approval timelines remain uncertain.
What's important to understand about all of this research: the positive results have been generated in carefully controlled settings with thorough screening, trained professionals, and structured integration. Whether similar results occur in less rigorous real-world settings is a question the field is still answering.
What It's Not
Given the amount of misconception surrounding this topic, being clear about what psychedelic therapy isn't may be as useful as defining what it is.
It's not taking psychedelics recreationally and calling it therapy. The therapeutic framework — screening, preparation, supervised session, integration — is what makes it therapy. Without that framework, it's drug use, which may or may not be beneficial but isn't what the research has studied.
It's not a cure for anything. No serious researcher or clinician in this field uses the word "cure." The evidence shows that psychedelic therapy can produce significant, sometimes dramatic, improvements in certain conditions for certain people. But it doesn't work for everyone, effects can fade, and it's not appropriate for all conditions or all individuals.
It's not an alternative to conventional mental health care. For most people, psychedelic therapy makes most sense as one component within broader mental health care — alongside ongoing therapy, lifestyle factors, medication when appropriate, and social support. Abandoning conventional care in favor of psychedelic therapy alone is not what the evidence supports.
It's not without risks. Psychedelic substances can produce intense psychological experiences, interact dangerously with certain medications (particularly MAOIs with ayahuasca, and SSRIs with psilocybin to a lesser degree), and are contraindicated for people with certain psychiatric conditions including psychotic disorders and bipolar I disorder. These risks are manageable in proper clinical settings but real.
It's not widely available yet. Despite the attention it receives, psychedelic therapy remains limited in accessibility. Psilocybin is available only in Oregon, Colorado, and soon New Mexico. Ketamine is broadly available but often expensive and rarely covered by insurance. MDMA therapy is not currently available outside clinical trials. The gap between media coverage and actual access remains substantial.
What's Actually Available Right Now in the US
If you're reading this and wondering what you can actually access today, here's the honest landscape as of 2026.
Ketamine therapy — available in all 50 states. Thousands of clinics offer ketamine infusions, and esketamine (Spravato) is available through approved medical providers. This is the most accessible form of psychedelic-adjacent therapy, though costs vary significantly and insurance coverage remains inconsistent. Typical cost for a ketamine infusion series runs $2,400 to $4,800 for 4-6 sessions.
Psilocybin therapy — available in Oregon and Colorado. Both states have licensed programs allowing supervised psilocybin sessions at approved centers without requiring a medical diagnosis. Sessions range from roughly $750 for group formats to $4,000+ for individual sessions. No insurance coverage currently exists. New Mexico's medical program is expected to launch by December 2026.
Clinical trials — available at select research institutions. Active clinical trials for psilocybin and other substances are recruiting participants at universities and medical centers across the country. These trials typically provide treatment at no cost but have specific eligibility criteria. ClinicalTrials.gov maintains a searchable database of active studies.
Everything else — not legally available in the US. MDMA therapy, ayahuasca ceremonies, ibogaine treatment, and other modalities are either not approved, only available internationally, or accessible only through narrow religious exemptions. Marketing that suggests otherwise deserves careful scrutiny.
How to Think About Whether It Might Be Right for You
If psychedelic therapy has caught your attention, a few honest questions are worth considering before going further.
What are you hoping to address? The strongest evidence exists for treatment-resistant depression and end-of-life anxiety. Evidence for other conditions is developing. Having clarity about what you're seeking treatment for helps determine whether psychedelic therapy is supported by current evidence for your situation.
Have you tried conventional approaches? For most conditions, evidence-based conventional treatments (therapy, medication) remain the appropriate first line. Psychedelic therapy shows particular promise for people who haven't responded adequately to conventional treatment. Jumping to psychedelic therapy before trying established approaches isn't what the research supports.
Do you have any contraindications? Personal or family history of psychotic disorders, bipolar I disorder, certain cardiac conditions, or current use of specific medications may rule out psychedelic therapy entirely. This screening needs to happen with a qualified clinician before anything else.
Can you commit to the full process? The value of psychedelic therapy comes from the complete framework — preparation, session, and especially integration. If you're looking for a quick fix without the surrounding work, the outcomes are likely to be disappointing regardless of which substance or setting you choose.
Are you prepared for the cost? Most forms of psychedelic therapy remain expensive and largely out-of-pocket. Understanding the financial commitment upfront, including potential travel and integration therapy costs, prevents difficult surprises later.
Where to Learn More
This article is designed as a starting point, not an endpoint. Depending on what resonated, several of our more detailed guides may be useful next steps.
If you're interested in understanding the specific substances and how they compare, our comparison of ketamine vs psilocybin retreats walks through the practical differences.
If depression is what you're considering psychedelic therapy for, our guide to psilocybin for depression covers the clinical research in detail.
If you're already leaning toward trying it and want to understand what the experience involves, our guide to what to expect at your first psychedelic retreat walks through the full process.
If you're on antidepressants and wondering about compatibility, our guide to psilocybin and antidepressants covers the medication interactions honestly.
If you want to compare specific licensed retreat centers, our directory of verified Oregon and Colorado retreats lets you evaluate options side by side.
And if you want to understand the safety profile before anything else, our complete guide to psilocybin safety covers side effects, contraindications, and who should not use it.
This article is for general informational purposes only and does not constitute medical advice. Psychedelic therapy involves controlled substances with specific medical, psychiatric, and legal considerations. Always consult qualified medical and mental health professionals before making treatment decisions. If you are experiencing a mental health crisis, please contact a crisis service in your area.
